ABI Genetic Analyzer-DNA Sequencer 3100

目前的提案是由科罗拉多大学健康科学中心的一组主要研究人员提出的，他们迫切需要高通量和自动化测序和基因分型作为主要研究工具。这项提议的目标是筹集资金购买新的应用生物系统遗传分析仪-DNA Sequencer 3100，以满足科罗拉多大学健康科学中心校园不断扩大的用户群体日益增长的需求。主要的用户群由科罗拉多大学医学院现有的糖尿病和内分泌研究中心(DERC)的教职员工组成。用户组包括芭芭拉·戴维斯儿童糖尿病中心的8名主要调查人员，包括执行主任(G.Eisenbarth)和研究主任(J.Hutton)，以及其他UCHSC调查人员，他们是DERC成员，包括临床免疫学负责人(B.Kotzin)。在这项申请的时候，主要用户是NIH每年超过400万美元的支持的接受者。所要求的仪器将缓解目前由1998年购买并由新成立的DERC分子核心操作的单一毛细ABI 310测序仪向用户群体提供的长期积压的测序服务。所要求的仪器将使用位于芭芭拉·戴维斯儿童糖尿病中心的DERC核心设施进行操作和管理，它的获得将使用户组能够更有效地执行高通量DNA测序。目前的仪器一次处理一个样本，而所请求的设备将允许每小时同时处理36个样本。将收取使用费，为仪器的管理和维护提供资金。尽管预计使用量将提供足够的资金，但这些费用不包括的运营成本将由芭芭拉·戴维斯中心用DERC提供的资金吸收。一个由DERC分子核心主管(L.Sussel和J.Hutton)、两名用户代表(一名BDC和一名非BDC)以及核心经理(S.Hawkes)组成的咨询小组将为所有用户提供平衡的管理政策。

The current proposal is from a group of principal investigators at the University of Colorado Health Sciences Center who have a pressing need for high throughput and automated sequencing and genotyping as a primary research tool. The goal of this proposal is to generate funds to purchase a new Applied Biosystems Genetic Analyzer-DNA Sequencer 3100 to accommodate the increasing demands of the expanding user group at the University of Colorado Health Sciences Center campus. The dominant user group is comprised of faculty members in the existing Diabetes and Endocrinology Research Center (DERC) at the University of Colorado School of Medicine. The user group includes 8 principal investigators at the Barbara Davis Center for Childhood Diabetes, including its Executive Director (G. Eisenbarth) and Research Director (J. Hutton) and additional UCHSC investigators who are DERC members, including the Head of Clinical Immunology (B. Kotzin). At the time of this application, the major users are recipients of over 4 million dollars in yearly NIH support. The instrument requested will alleviate the chronic backlog of sequencing services presently provided to the user group by a single capillary ABI 310 sequencer purchased in 1998 and operated by the newly established DERC molecular core. The instrument requested will be operated and managed using the DERC core facility at the Barbara Davis Center for Childhood Diabetes and its acquisition will permit the user group to more efficiently perform high throughput DNA sequencing. The current instrumentation processes one sample at a time whereas the requested equipment will allow the simultaneous processing of 36 samples per hour. User fees will be charged to fund the management and maintenance of the instrument. Although projected usage should provide enough funding, operating costs not covered by these fees will be absorbed by the Barbara Davis Center with funds provided by the DERC. An advisory group comprised of the DERC molecular core directors (L.Sussel and J. Hutton), two user representatives (one BDC and one non-BDC), and the core manager (S. Hawkes) will provide a balanced management policy for all users.